Pain, PostoperativePhase 3NCT00551135
Surgical Pain After Inguinal Hernia Repair (SPAIHR)
A Phase 3 study testing Pregabalin in people with Pain, Postoperative and Hernia, Inguinal, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 42 sites in 6 countries.
Trial summary
The purpose of this study is to test whether pregabalin added to the standard of care with dosing starting preoperatively and continuing for 1 week post surgery will decrease the intensity of acute post-operative pain following inguinal hernia repair. Read more about this study
- Who is it for?
- Ages 17 to 75 years, men only
- Conditions the study is for
- Pain, Postoperative, Hernia, Inguinal
- What is being tested?
- Pregabalin
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 425 participants
- Where
- 42 sitesin 6 countries
- Study dates
- Jan 2008to Sep 2009
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 17 to 75 years
- Men only
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- The subject will have elective ( the subject chooses, but does not have to undergo surgery for an emergency) open unilateral inguinal herniorraphy (hernia repair), using mesh Lichtenstein surgery procedure and under general anesthesia and fentanyl or sufentanil/propofol initiation and sevoflurane or isoflurane maintenance plus local anesthetic infiltration at the conclusion of surgery. Study surgery should be anticipated to be in the morning.
- Expected to be able to use and tolerate non-steroidal anti-inflammatory drugs (such as naproxen), tramadol, oxycodone, and acetaminophen/paracetamol for pain control after surgery.
- The subject will be available for a visit within 72 hours of the day of surgery if not admitted the night before for baseline assessments before taking any study medication, and then to receive study medication prior to the day before surgery.
- The subject is expected and agrees to remain at the hospital (or intermediate care facility) for a minimum of 3 hours following surgery.
Who cannot join
- Subjects with non elective or emergency surgery (must have the surgery no matter what), or hernia with incarceration (the trapping of abdominal contents within the hernia itself).
- Subjects with hernia repair that is not a primary repair. The planned use of nerve block or spinal/epidural/paravertebral anesthesia or surgery is not planned with general anesthesia.
- Subjects that are not allowed to receive the anesthesia agents indicated per protocol and general anesthesia.
Trial locations and contacts
42 sites in 6 countries.
42 sites in 6 countries
United States24 sites
Pfizer Investigational Site
Birmingham, Alabama, 35235
Pfizer Investigational Site
Columbus, Ohio, 43210
Pfizer Investigational Site
Dallas, Texas, 75390-7208
Pfizer Investigational Site
Durham, North Carolina, 27710
Pfizer Investigational Site
Glendale, California, 91206
Pfizer Investigational Site
Hermitage, Tennessee, 37075
Pfizer Investigational Site
Hermitage, Tennessee, 37076
Pfizer Investigational Site
Houston, Texas, 77024
Pfizer Investigational Site
Houston, Texas, 77054
Pfizer Investigational Site
Houston, Texas, 77091
Pfizer Investigational Site
Houston, Texas, 77098
Pfizer Investigational Site
Humble, Texas, 77338
Pfizer Investigational Site
Kingwood, Texas, 77339
Pfizer Investigational Site
Knoxville, Tennessee, 27920
Pfizer Investigational Site
Knoxville, Tennessee, 37920
Pfizer Investigational Site
Laguna Hills, California, 92653
Pfizer Investigational Site
Lake Worth, Florida, 33462
Pfizer Investigational Site
Nashville, Tennessee, 37203
Pfizer Investigational Site
Pasadena, California, 91105
Pfizer Investigational Site
Pensacola, Florida, 32504
Pfizer Investigational Site
Pittsburgh, Pennsylvania, 15232
Pfizer Investigational Site
Rochester, Minnesota, 55905
Pfizer Investigational Site
Rochester, New York, 14642
Pfizer Investigational Site
Stony Brook, New York, 11794-8480
Sweden5 sites
Pfizer Investigational Site
Gävle, 801-87
Pfizer Investigational Site
Landskrona, 261 24
Pfizer Investigational Site
Mora, SE-792 85
Pfizer Investigational Site
Örebro, 701 85
Pfizer Investigational Site
Skellefteå, 931 86
Canada4 sites
Pfizer Investigational Site
Charlottetown, Prince Edward Island, C1A 8T5
Pfizer Investigational Site
London, Ontario, N6A 4V2
Pfizer Investigational Site
London, Ontario, N6A 5A5
Pfizer Investigational Site
Québec, Quebec, G1V 4G2
India4 sites
Pfizer Investigational Site
Delhi, 110 095
Pfizer Investigational Site
Madurai, Tamil Nadu, 625 107
Pfizer Investigational Site
Pune, Maharashtra, 411011
Pfizer Investigational Site
Vadodara, Gujarat, 390001
Spain4 sites
Pfizer Investigational Site
Alcorcón, Madrid, 28922
Pfizer Investigational Site
Barcelona, 08036
Pfizer Investigational Site
Madrid, 28006
Pfizer Investigational Site
Madrid, 28031
About this study
Official title: A Randomized, Double Blind Multi Center Dose Ranging Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo In The Adjunctive Treatment Of Post Surgical Pain After Primary Inguinal Hernia Repair
The purpose of this study is to test whether pregabalin added to the standard of care with dosing starting preoperatively and continuing for 1 week post surgery will decrease the intensity of acute post-operative pain following inguinal hernia repair.
- Conditions
- Pain, Postoperative, Hernia, Inguinal
- Being tested
- Pregabalin, placebo
- Keywords
- postoperative pain chronic pain
- Medical subject headings
- Pain, Postoperative, Hernia, Inguinal
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PregabalinDrug
150 mg BID
placeboDrug
Placebo
PregabalinDrug
75 mg BID
PregabalinDrug
25 mg BID
| Study group | Role | What they receive |
|---|---|---|
| 3 | Experimental | Not described Receives: Drug: Pregabalin |
| 4 | Placebo comparator | Not described Receives: Drug: placebo |
| 2 | Experimental | Not described Receives: Drug: Pregabalin |
| 1 | Experimental | Not described Receives: Drug: Pregabalin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Modified Brief Pain Inventory-Short Form (mBPI-sf): Worst Pain 24 Hours Post Surgery
m-BPI-sf: a self-administered 11-point Likert rating scale to rate pain in the past 24 hours. A single item pertains to worst pain in the past 24 hours: range of 0 (no pain) to 10 (worst imaginable pain).
Measured: 24 hours post surgery
Secondary outcomes (26)
Numeric Rating Scale (NRS): Current Pain With Movement - Sitting
NRS: a self-administered questionnaire to rate pain. A single item asks to rate pain with movement caused by sitting (sitting in a standardized fashion after being in a fully supine position); range: 0 (no pain) to 10 (worst pain).
Measured: Baseline; 2 hours (h) before surgery (BS); 1, 2, and 3 h post surgery (PS); Days 2, 3, 4, 5, 6, and 7 PS; and End of Treatment (EOT [Day 7 PS or Early Termination])
Numeric Rating Scale (NRS): Current Pain With Movement - Walking
NRS: a self-administered questionnaire to rate pain. A single item asks to rate pain with movement caused by walking (rising from sitting position and walking approximately 5 meters or 16 feet at a moderate pace); range: 0 (no pain) to 10 (worst pain).
Measured: Baseline; 2 hours (h) before surgery (BS); 1, 2, and 3 h post surgery (PS); Days 2, 3, 4, 5, 6, and 7 PS; and End of Treatment (EOT [Day 7 PS or Early Termination])
Numeric Rating Scale (NRS): Current Pain With Movement - Coughing
NRS: a self-administered questionnaire to rate pain. A single item asks to rate pain with movement caused by coughing (coughing two times while sitting); range: 0 (no pain) to 10 (worst pain)
Measured: Baseline; 2 hours (h) before surgery (BS); 1, 2, and 3 h post surgery (PS); Days 2, 3, 4, 5, 6, and 7 PS; and End of Treatment (EOT [Day 7 PS or Early Termination])
Numeric Rating Scale (NRS): Current Pain With Movement - Area Under the Curve (AUC) for Sitting, Walking, and Coughing
NRS: a self-administered questionnaire to rate pain. AUC from 1 h PS through 48 h PS for ratings of pain caused by movements of sitting, walking, and coughing; Range: 0 (no pain) to 10 (worst pain).
Measured: 1 hour through 48 hours post surgery
Numerical Rating Scale (NRS): Current Pain at Rest
NRS: a self-administered questionnaire to rate pain. A single item asks participant to rate current pain at rest (preceding pain with movement); range: 0 (no pain) to 10 (worst pain).
Measured: 2 hours (h) before surgery (BS); 1, 2, and 3 h post surgery (PS); Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 PS
Numeric Rating Scale (NRS): Current Pain at Rest - Area Under the Curve (AUC)
NRS: a self-administered questionnaire to rate pain. AUC for a single item asking participant to rate current pain at rest (preceding pain with movement); range: 0 (no pain) to 10 (worst pain).
Measured: 1 through 48 hours post surgery (PS)
Numeric Rating Scale (NRS): Average Pain
NRS: a self-administered questionnaire to rate pain. A single item asks participant to rate pain on average in the last 24 hours; range: 0 (no pain) to 10 (worst pain).
Measured: 2 hours (h) before surgery (BS); 1, 2, and 3 h post surgery (PS); Days 1, 2, 3, 4, 5, 6, and 7 PS
Time From End of Surgery to First Rescue Medication
Rescue medication includes both naproxen and narcotic medication (including tramadol and opioid analgesics). For subjects without use of rescue medication, the time-to-event variable is censored at the Beginning of Taper Visit (Day 7 PS) or at time of withdrawal.
Measured: Day 1 through Day 7 post surgery
Time From End of Surgery to Reach a Total Score of at Least 9 on the Post-Anesthetic Discharge Scoring System (PADS)
PADS is a 5-item scale (individual item range: 0-2; higher scores indicating better readiness for hospital discharge). Total score range: 0-10, with 9 or higher indicating eligibility for discharge. End of surgery is time of transfer to post-anesthesia care unit (PACU). Subjects who did not reach a score of 9 on PADS were censored at the date and time of discharge.
Measured: Day 1
Time From End of Surgery to Discharge From Post-Anesthesia Care Unit (PACU)
Measured: Day 1
Daily Sleep Interference Rating Scale (DSIRS) Score
DSIRS: self-administered 11-point Likert scale ranging from 0 (pain does not interfere with sleep) to 10 (pain completely interferes with sleep [unable to sleep due to pain]) during past 24-hour period. Higher score indicates a greater level of sleep disturbance. Performed daily on awakening, prior to taking study medication.
Measured: Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 post surgery (PS)
Total Cumulative Dose of Opioids and Tramadol Used During and After Surgery
Total cumulative dose of opioids and tramadol administered by any route during surgery and postoperatively. Dose of tramadol calculated as milligrams (mg) of oral morphine equivalent.
Measured: 24, 48, and 72 hours (h) post surgery (PS), and Days 4, 5, 6, and 7 PS
Amount of Non-opioid Rescue Medication (Naproxen and Antiemetic Medications) Used During the Study
Total cumulative dose of naproxen calculated in milligrams (mg) from the end of surgery up to and including Day 7 after surgery.
Measured: End of Surgery through Day 7 post surgery
Total Clinically Meaningful Event (CME) Score and Cumulative Total Distinct CME Score Using the Opioid-Related Symptom Distress Scale (OR-SDS)
OR-SDS: a self-administered assessment of 10 common opioid-related side effects (symptoms). A CME is a severe or very severe symptom (or moderate or greater severity symptom of confusion). The Total Distinct CME score is the sum of CMEs across symptoms (range: 0 [none] to 10 [10 CMEs]); the Cumulative Total Distinct (CT Distinct) CME score is the sum of Total Distinct CME scores at observation and prior observations. The Total CME score is the same as the Total Distinct CME score except that only 1 CME is counted if both nausea and vomiting (or retching) occur (range: 0 [none] to 9 [9 CMEs]).
Measured: 3, 24, and 72 hours (h) Post-Surgery (PS), and End of Treatment (EOT [Day 7 PS or Early Termination])
Participants With Clinically Meaningful Events (CMEs) for Individual Symptoms Using the Opioid-Related Symptom Distress Scale (OR-SDS)
OR-SDS: a self-administered assessment of 10 common opioid-related side effects (symptoms). A CME is a severe or very severe symptom (or moderate or greater severity symptom of confusion). For individual symptom categories, the number of subjects who experienced at least one CME. Concentrate (concentr).
Measured: 3, 24, and 72 hours (h) post surgery (PS), and End of Treatment (EOT [Day 7 PS or Early Termination])
Subject Global Evaluation of Study Medication (GESM)
GESM is a self-administered overall impression (global evaluation) of study medication received for pain; 4 categories: poor, fair, good, and excellent.
Measured: 24 hours (h) post surgery (PS) and End of Treatment (EOT [Day 7 PS or Early Termination])
Participants With Wound Healing Complications
Investigator-assigned mutually exclusive categories of: 1) no surgical wound complication, 2) superficial incisional surgical site infection, 3) deep incisional surgical site infection, 4) organ or space surgical site infection, or 5) non-infectious wound healing complication.
Measured: Day 7 post surgery (PS) and up to 30 days PS
Participants With Physician Contacts Post-discharge
Number of participants who answered "yes" to the Post-Surgery Contact question: "From the time you were discharged from the hospital, did you have to contact any type of physician because of pain, difficulty getting up and walking about, or difficulty with passing urine?"
Measured: 24 and 72 hours (h) post surgery (PS)
Baseline and Change From Baseline in Anxiety Visual Analog Scale (VAS) Score
Anxiety VAS is a single-item self-administered continuous measure of anxiety using a 100-millimeter (mm) line on which the subject is asked to place a mark indicating the intensity of current anxiety. The score is the distance in mm from the left-most point on the line to the subject's mark; range: 0 (Not at all anxious) at the left-most point to 100 (Extremely anxious) at the right-most point. Performed prior to blood draws.
Measured: Baseline; 2 hours (h) before surgery (BS); 1, 2, and 3 h PS; Days 2, 3, 4, 5, 6, 7, 8, and 9 PS
Baseline and Change From Baseline in EuroQol (EQ-5D) Health State Profile Score
EQ-5D is a self-administered questionnaire to assess health-related quality of life in 5 domains (mobility, self care, usual activities, pain or discomfort, and anxiety or depression). Scores from the 5 domains are used to calculate a single index value: the Health State Profile Score; range: 0.0 (death) to 1.0 (perfect health), higher scores indicating better health state.
Measured: Baseline and End of Treatment (EOT [Day 7 post surgery or Early Termination])
Change From Baseline in Pain Catastrophizing Scale (PCS) Total Score and Subscales
The PCS is a self-administered questionnaire with 13 items, each scored from 0 (not at all) to 4 (all the time) for extent to which participant catastrophizes postoperative pain. Total score is sum of scores for all questions (range: 0 to 52); Subscale scores: Rumination (sum of scores for 4 items; range: 0 to 16); Magnification (sum of scores for 3 items; range: 0 to 12); and Helplessness (sum of scores for 6 items; range: 0 to 24); higher scores mean a greater extent of pain catastrophizing.
Measured: 3 hours (h) post surgery (PS) and End of Treatment (EOT [Day 7 PS or Early Termination])
Relationship Between Baseline and Postoperative Pain Catastrophizing Scale (PCS) Score and Severity of Acute Pain and to Response to Therapy
The PCS is a self-administered questionnaire with 13 items, each scored from 0 (not at all) to 4 (all the time) for extent to which participant catastrophizes postoperative pain. Total score is sum of scores for all items (range: 0 to 52); higher scores mean a greater extent of pain catastrophizing.
Measured: Baseline and Days 1 and 7 post surgery (PS)
Baseline and Change From Baseline in Short Form Acute Health Survey 12-Item Version (SF-12v2) Physical Component Summary Score (PCSS) and Mental Component Summary Score (MCSS)
PCSS and MCSS are component summary scores from the self-administered SF-12v2 acute health quality of life, norm-based survey. PCSS range: 4.95 to 76.13; MCSS range: -0.79 to 79.69; lowest scores mean very much below and highest scores mean very much above the general population average.
Measured: Baseline and End of Treatment (EOT [Day 7 post surgery or Early Termination])
Participants With Chronic Postoperative Pain
Number of participants who reported surgery-related pain at assessment (by answering 'yes' to a single question: "In the last 24 hours, have you had pain in the area affected by your surgery?")
Measured: 1, 3, and 6 months (mo) post surgery (PS)
Chronic Postoperative Pain: Pain Severity Index Score and Pain Interference Index Score on the Modified Brief Pain Inventory-Short Form (mBPI-sf)
m-BPI-sf: a self-administered 11-point Likert rating scale to rate pain in the past 24 hours. Pain interference index score is mean of 7 individual item scores for interference of pain with functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life); range: 0 (does not interfere) to 10 (completely interferes with functional activities). Pain severity index score is mean of 4 individual item scores for pain severity (pain right now, and worst, least, and average pain); range: 0 (no pain) to 10 (worst imaginable pain).
Measured: 1, 3, and 6 months (mo) post surgery (PS)
Chronic Postoperative Pain: Total Score and Subscale Scores Using the Neuropathic Pain Symptom Inventory (NPSI)
NPSI: a 12-item self-administered questionnaire to assess the characteristics of neuropathic pain on average in the last 24 hours. 5 subscale scores include: burning spontaneous (spont.) pain, pressing spont. pain, paroxysmal pain, evoked pain, and paresthesia or dysesthesia (paresth/dysesth) (range: 0 [no pain] to 10 [worst pain imaginable]); total score calculated from the 5 pain subscores (range: 0 to 0.5), higher scores meaning worse pain.
Measured: 1, 3, and 6 months (mo) post surgery (PS)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Oct 2007 (estimated)
- Study startJan 2008
- Primary completionJun 2009
- Study completionSep 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Pain, PostoperativeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 425 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00551135
- Sponsor's protocol ID
- A0081171
- Status last verified
- Jun 2010
- First submitted
- 26 Oct 2007
- Last updated
- 25 Jan 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Singla NK, Chelly JE, Lionberger DR, Gimbel J, Sanin L, Sporn J, Yang R, Cheung R, Knapp L, Parsons B. Pregabalin for the treatment of postoperative pain: results from three controlled trials using different surgical models. J Pain Res. 2014 Dec 23;8:9-20. doi: 10.2147/JPR.S67841. eCollection 2015.
PubMed 25565885
Study at a glance
From the registry record, last updated by the sponsor on 25 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double Blind Multi Center Dose Ranging Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo In The Adjunctive Treatment Of Post Surgical Pain After Primary Inguinal Hernia Repair
- ClinicalTrials.gov ID
- NCT00551135
- Acronym / sponsor ID
- A0081171
- Conditions
- Pain, Postoperative, Hernia, Inguinal
- Keywords
- postoperative pain chronic pain
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 425 participants (actual)
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Industry (pharma, biotech, devices)
- Study start
- Jan 2008
- Primary completion
- Jun 2009 (actual)
- Study completion
- Sep 2009 (actual)
- First posted
- 30 Oct 2007 (estimated)
- Results
- Posted 15 Jul 2010
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to test whether pregabalin added to the standard of care with dosing starting preoperatively and continuing for 1 week post surgery will decrease the intensity of acute post-operative pain following inguinal hernia repair.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| 3 | Experimental | Drug: Pregabalin |
| 4 | Placebo comparator | Drug: placebo |
| 2 | Experimental | Drug: Pregabalin |
| 1 | Experimental | Drug: Pregabalin |
Who may qualify
- Ages
- 17 to 75 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- The subject will have elective ( the subject chooses, but does not have to undergo surgery for an emergency) open unilateral inguinal herniorraphy (hernia repair), using mesh Lichtenstein surgery procedure and under general anesthesia and fentanyl or sufentanil/propofol initiation and sevoflurane or isoflurane maintenance plus local anesthetic infiltration at the conclusion of surgery. Study surgery should be anticipated to be in the morning.
- Expected to be able to use and tolerate non-steroidal anti-inflammatory drugs (such as naproxen), tramadol, oxycodone, and acetaminophen/paracetamol for pain control after surgery.
- The subject will be available for a visit within 72 hours of the day of surgery if not admitted the night before for baseline assessments before taking any study medication, and then to receive study medication prior to the day before surgery.
- The subject is expected and agrees to remain at the hospital (or intermediate care facility) for a minimum of 3 hours following surgery.
Key exclusion criteria (3 listed)
- Subjects with non elective or emergency surgery (must have the surgery no matter what), or hernia with incarceration (the trapping of abdominal contents within the hernia itself).
- Subjects with hernia repair that is not a primary repair. The planned use of nerve block or spinal/epidural/paravertebral anesthesia or surgery is not planned with general anesthesia.
- Subjects that are not allowed to receive the anesthesia agents indicated per protocol and general anesthesia.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pregabalin150 mg BID | Drug | 3 |
| placeboPlacebo | Drug | 4 |
| Pregabalin75 mg BID | Drug | 2 |
| Pregabalin25 mg BID | Drug | 1 |
Primary outcome
Modified Brief Pain Inventory-Short Form (mBPI-sf): Worst Pain 24 Hours Post Surgery
Time frame: 24 hours post surgery
m-BPI-sf: a self-administered 11-point Likert rating scale to rate pain in the past 24 hours. A single item pertains to worst pain in the past 24 hours: range of 0 (no pain) to 10 (worst imaginable pain).
26 secondary outcomes
Numeric Rating Scale (NRS): Current Pain With Movement - Sitting
Time frame: Baseline; 2 hours (h) before surgery (BS); 1, 2, and 3 h post surgery (PS); Days 2, 3, 4, 5, 6, and 7 PS; and End of Treatment (EOT [Day 7 PS or Early Termination])
Numeric Rating Scale (NRS): Current Pain With Movement - Walking
Time frame: Baseline; 2 hours (h) before surgery (BS); 1, 2, and 3 h post surgery (PS); Days 2, 3, 4, 5, 6, and 7 PS; and End of Treatment (EOT [Day 7 PS or Early Termination])
Numeric Rating Scale (NRS): Current Pain With Movement - Coughing
Time frame: Baseline; 2 hours (h) before surgery (BS); 1, 2, and 3 h post surgery (PS); Days 2, 3, 4, 5, 6, and 7 PS; and End of Treatment (EOT [Day 7 PS or Early Termination])
Numeric Rating Scale (NRS): Current Pain With Movement - Area Under the Curve (AUC) for Sitting, Walking, and Coughing
Time frame: 1 hour through 48 hours post surgery
Numerical Rating Scale (NRS): Current Pain at Rest
Time frame: 2 hours (h) before surgery (BS); 1, 2, and 3 h post surgery (PS); Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 PS
Numeric Rating Scale (NRS): Current Pain at Rest - Area Under the Curve (AUC)
Time frame: 1 through 48 hours post surgery (PS)
Numeric Rating Scale (NRS): Average Pain
Time frame: 2 hours (h) before surgery (BS); 1, 2, and 3 h post surgery (PS); Days 1, 2, 3, 4, 5, 6, and 7 PS
Time From End of Surgery to First Rescue Medication
Time frame: Day 1 through Day 7 post surgery
Time From End of Surgery to Reach a Total Score of at Least 9 on the Post-Anesthetic Discharge Scoring System (PADS)
Time frame: Day 1
Time From End of Surgery to Discharge From Post-Anesthesia Care Unit (PACU)
Time frame: Day 1
Daily Sleep Interference Rating Scale (DSIRS) Score
Time frame: Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 post surgery (PS)
Total Cumulative Dose of Opioids and Tramadol Used During and After Surgery
Time frame: 24, 48, and 72 hours (h) post surgery (PS), and Days 4, 5, 6, and 7 PS
Amount of Non-opioid Rescue Medication (Naproxen and Antiemetic Medications) Used During the Study
Time frame: End of Surgery through Day 7 post surgery
Total Clinically Meaningful Event (CME) Score and Cumulative Total Distinct CME Score Using the Opioid-Related Symptom Distress Scale (OR-SDS)
Time frame: 3, 24, and 72 hours (h) Post-Surgery (PS), and End of Treatment (EOT [Day 7 PS or Early Termination])
Participants With Clinically Meaningful Events (CMEs) for Individual Symptoms Using the Opioid-Related Symptom Distress Scale (OR-SDS)
Time frame: 3, 24, and 72 hours (h) post surgery (PS), and End of Treatment (EOT [Day 7 PS or Early Termination])
Subject Global Evaluation of Study Medication (GESM)
Time frame: 24 hours (h) post surgery (PS) and End of Treatment (EOT [Day 7 PS or Early Termination])
Participants With Wound Healing Complications
Time frame: Day 7 post surgery (PS) and up to 30 days PS
Participants With Physician Contacts Post-discharge
Time frame: 24 and 72 hours (h) post surgery (PS)
Baseline and Change From Baseline in Anxiety Visual Analog Scale (VAS) Score
Time frame: Baseline; 2 hours (h) before surgery (BS); 1, 2, and 3 h PS; Days 2, 3, 4, 5, 6, 7, 8, and 9 PS
Baseline and Change From Baseline in EuroQol (EQ-5D) Health State Profile Score
Time frame: Baseline and End of Treatment (EOT [Day 7 post surgery or Early Termination])
Change From Baseline in Pain Catastrophizing Scale (PCS) Total Score and Subscales
Time frame: 3 hours (h) post surgery (PS) and End of Treatment (EOT [Day 7 PS or Early Termination])
Relationship Between Baseline and Postoperative Pain Catastrophizing Scale (PCS) Score and Severity of Acute Pain and to Response to Therapy
Time frame: Baseline and Days 1 and 7 post surgery (PS)
Baseline and Change From Baseline in Short Form Acute Health Survey 12-Item Version (SF-12v2) Physical Component Summary Score (PCSS) and Mental Component Summary Score (MCSS)
Time frame: Baseline and End of Treatment (EOT [Day 7 post surgery or Early Termination])
Participants With Chronic Postoperative Pain
Time frame: 1, 3, and 6 months (mo) post surgery (PS)
Chronic Postoperative Pain: Pain Severity Index Score and Pain Interference Index Score on the Modified Brief Pain Inventory-Short Form (mBPI-sf)
Time frame: 1, 3, and 6 months (mo) post surgery (PS)
Chronic Postoperative Pain: Total Score and Subscale Scores Using the Neuropathic Pain Symptom Inventory (NPSI)
Time frame: 1, 3, and 6 months (mo) post surgery (PS)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jan 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 25565885Singla NK, Chelly JE, Lionberger DR, Gimbel J, Sanin L, Sporn J, Yang R, Cheung R, Knapp L, Parsons B. Pregabalin for the treatment of postoperative pain: results from three controlled trials using different surgical models. J Pain Res. 2014 Dec 23;8:9-20. doi: 10.2147/JPR.S67841. eCollection 2015.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Pain, Postoperative
Active, not recruiting
Dance Study for Post-surgical Pain in Breast Cancer Survivors
Breast Cancer, Survivorship
RecruitingPhase 2/3
Gabapentin to Reduce Opioid Use Postoperatively (GROUP) in Children
Pain, Postoperative
Not yet recruitingPhase 3
Extended Post-Operative Oral Tranexamic Acid Dosing After ACL Reconstruction
Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture
Active, not recruiting
Pivotal Study on the NOVABLOC System for Patients Undergoing Primary Total Knee Arthroplasty
Pain
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
42 sites in 6 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Pregabalin in people with Pain, Postoperative and Hernia, Inguinal, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 42 sites in 6 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 42 sites in United States, Sweden, Canada, India, Spain and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 15 Jul 2010). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Modified Brief Pain Inventory-Short Form (mBPI-sf): Worst Pain 24 Hours Post Surgery (time frame: 24 hours post surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00551135, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2021.